Company Active LTD

Company profile

Cellesce Limited

UK company 08484947, incorporated on 12 April 2013.

Cellesce Growing and scale up of patient derived organoids

Cellesce Limited is a UK company with status Active founded in 2013 based in Wales.

Company number
08484947
Incorporated
12 Apr 2013
Companies House status
Active

Company identity

Founded / incorporated
12 April 2013

Company number 08484947

Verify at Companies House
Legal name
CELLESCE LIMITED
Company type
Private Limited Company
Region
Wales
Registered address
1 LONGWOOD DRIVE
CARDIFF
WALES
CF14 7HY
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

2 levels 1 ultimate controller
1
Company Active LTD
Cellesce Limited
CRN 08484947
2
Direct controller Active LTD
3
Ultimate controller
02103594
CRN 02103594

Company events

Reference milestones and recent Companies House filing stream events.

6 events
26 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

12 Aug
2026

Dissolution Application Strike Off Company

Dissolution

DS01 | Transaction MzUzNzgzODQ0MGFkaXF6a2N4

Published 12 Aug 2026 09:09

30 Jun
2026

Accounts due

Accounts Due

Next accounts due date

12 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2024

Accounts filed

Accounts

Last accounts made up date

12 Apr
2013

Incorporated

Inception

Company registered at Companies House

Public funding

7 awards
First funded
2014
Funded years
2014, 2018, 2019, 2020, 2021
Age at first award
1 years

Projects

2021 Collaborative R&D Lead participant

Scale-up of breast and colorectal cancer organoids for high throughput screening

29 Apr 2021 to 29 Apr 2023

Awarded
£1,285,785
Total cost £1,285,785

There is an urgent and unmet medical need to discover new cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a lab-based test system that can accurately predict the efficacy of novel compounds for further clinical development....

2021 Knowledge Transfer Partnership

Cardiff University and Cellesce Limited - P2

1 Mar 2021 to 31 Aug 2023

Awarded
Unknown

To implement an advanced data analysis pipeline to identify key morphometric signatures from 3D images of screened organoids in drug trials and to classify organoid response for the assessment of therapeutic efficacy for application in the pharmaceutical industry.

2021 Collaborative R&D

Fully synthetic animal-free scaffolds: the future of sustainable and scalable organoid culture

1 Jan 2021 to 30 Sep 2021

Awarded
£33,842
Total cost £42,302

Organoids are 3-dimensional (3D) clusters of stem cells that come together and emulate the microenvironment within individual organs, whether that be liver, kidney, heart, gut or other specific organs. Essentially, they can be viewed as miniature, simplified organs. They typically range in size from a few micrometers to five millimeters and there are pote...

2020 Feasibility Studies Lead participant

Commercialisation of Patient-derived breast cancer organoids for drug discovery

1 Jun 2020 to 30 Nov 2020

Awarded
£85,412
Total cost £85,412

no public description

2019 Knowledge Transfer Partnership

Cardiff University and Cellesce Limited - P1

1 Aug 2019 to 31 Dec 2022

Awarded
Unknown

To develop novel, real-time, cell ‘happiness’ assays to allow optimisation of the growth of patient samples in 3D mini organ-like cultures. These 'organoids' can be used in drug discovery and genetics research.

2018 Feasibility Studies Lead participant

Patient-derived breast cancer organoids to transform drug discovery screening assays

1 Jul 2018 to 31 Oct 2020

Awarded
£193,831
Total cost £276,901

"There is an urgent and unmet medical need to discover and develop new disease-modifying breast cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a test system that accurately predicts the efficacy of novel compounds for furt...

2014 Feasibility Studies Lead participant

Bioreactor and Bioprocessing of organoids to enable their market-wide drug screening application

1 Sep 2014 to 29 Feb 2016

Awarded
£93,747
Total cost £124,996

Organoid culture is a new technique that, unlike the use of cell lines, maintains tumour properties in the lab. Organoid cultures should improve the rate at which new drugs are discovered since they should lower the number of ineffective drugs that make their way through animal testing; this will directly lead to new, more effective drugs plus reductions ...

Product types

Collaborative R&D Feasibility Studies Knowledge Transfer Partnership